Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Cohen

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Plos One|July 5, 2013
Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting listDominique Prié, Anne Forand, Claire Francoz, et al.
Plos One|September 28, 2011
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenJade Ghosn, Constance Delaugerre, Philippe Flandre, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 26, 2015
Increasing mitochondrial muscle fatty acid oxidation induces skeletal muscle remodeling toward an oxidative phenotypeCarole Hénique, Abdelhak Mansouri, Eliska Vavrova, et al.
Antiviral Therapy|August 5, 2008
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trialBruno Spire, Fabienne Marcellin, Isabelle Cohen-Codar, et al.
Cell Reports|August 30, 2016
Disruption of the Phosphate Transporter Pit1 in Hepatocytes Improves Glucose Metabolism and Insulin Signaling by Modulating the USP7/IRS1 InteractionAnne Forand, Eugénie Koumakis, Alice Rousseau, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genesKatherine A Sutherland, Jean L Mbisa, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2010
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trialVéronique Avettand-Fenoel, Philippe Flandre, Marie-Laure Chaix, et al.
Oncogene|April 18, 2002
Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-X(L)Helena L A Vieira, Patricia Boya, Isabelle Cohen, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudineJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 30, 2015
Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapyTu-Anh Tran, Jade Ghosn, Véronique Avettand-Fenoël, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Plos One|July 5, 2013
Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting listDominique Prié, Anne Forand, Claire Francoz, et al.
Plos One|September 28, 2011
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimenJade Ghosn, Constance Delaugerre, Philippe Flandre, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 26, 2015
Increasing mitochondrial muscle fatty acid oxidation induces skeletal muscle remodeling toward an oxidative phenotypeCarole Hénique, Abdelhak Mansouri, Eliska Vavrova, et al.
Antiviral Therapy|August 5, 2008
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trialBruno Spire, Fabienne Marcellin, Isabelle Cohen-Codar, et al.
Cell Reports|August 30, 2016
Disruption of the Phosphate Transporter Pit1 in Hepatocytes Improves Glucose Metabolism and Insulin Signaling by Modulating the USP7/IRS1 InteractionAnne Forand, Eugénie Koumakis, Alice Rousseau, et al.
The Journal of Antimicrobial Chemotherapy|August 7, 2014
Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genesKatherine A Sutherland, Jean L Mbisa, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|March 20, 2010
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trialVéronique Avettand-Fenoel, Philippe Flandre, Marie-Laure Chaix, et al.
Oncogene|April 18, 2002
Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-X(L)Helena L A Vieira, Patricia Boya, Isabelle Cohen, et al.
The Journal of Antimicrobial Chemotherapy|March 18, 2008
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudineJade Ghosn, Marie-Laure Chaix, Gilles Peytavin, et al.
The Journal of Antimicrobial Chemotherapy|May 30, 2015
Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapyTu-Anh Tran, Jade Ghosn, Véronique Avettand-Fenoël, et al.
Pageof 3